Some of the best links we picked up around the internet
The FDA has cleared HuidaGene Therapeutics' investigational new drug application for HG202, the first CRISPR-Cas13 RNA-editing therapy to enter...
Allogene Therapeutics has activated the first clinical sites in a pivotal Phase 2 trial of cema-cel as first line consolidation treatment for large...